HF2906
Psilocybin therapeutic use program established; protections for registered patients, designated cultivators, registered facilitators, and health care practitioners established; rulemaking authorized; civil actions authorized; fees established; advisory committee established; criminal penalties provided; and money appropriated.
Legislative Session 94 (2025-2026)
Related bill: SF3971
AI Generated Summary
Purpose of the Bill
The bill aims to create a regulated program in Minnesota for the therapeutic use of psilocybin, a psychoactive compound found in certain mushrooms. This program is intended for individuals above the age of 21 with qualifying medical conditions, offering a legal framework for accessing psilocybin in a safe and therapeutic manner.
Main Provisions
- Psilocybin Therapeutic Use Program: Establishment of a program under the Minnesota Department of Health for the administration and use of psilocybin through supervised sessions, addressing patient safety and harm reduction.
- Eligibility and Enrollment: Individuals must be over 21, have a qualifying medical condition, and pass a health screening to enroll in the program starting January 1, 2027.
- Designation and Cultivation: Registered patients can personally cultivate psilocybin or designate someone to cultivate on their behalf. Specific rules govern the amount and safety protocols of cultivation.
- Facilitation and Supervision: Trained registered facilitators will oversee psilocybin administration sessions and are required to lead preparation and integration sessions.
- Regulation and Rulemaking: The Health and Agriculture Commissioners will set rules concerning qualifying conditions, cultivation limits, and facilitator qualifications.
Significant Changes to Existing Law
- Legal Protections: The bill includes protections against civil and criminal liabilities for participants, facilitators, and public employees associated with the program. It also restricts law enforcement from accessing registry data.
- Employment and Housing Protections: Protects registered patients and facilitators from discrimination in employment and housing based solely on their participation in the program.
- Advisory Committee: Formation of a Psychedelic Medicine Advisory Committee to guide the program's development and ensure ongoing evaluation.
Relevant Terms
psilocybin, therapeutic use, registered facilitators, designated cultivators, harm reduction, patient safety, advisory committee, cultivation, eligibility criteria, health screening, rulemaking, legal protections, discrimination in housing and employment.
Past committee meetings
You must be logged in to view 1 past legislative committee meetings.
Actions
| Date | Chamber | Where | Type | Name | Committee Name |
|---|---|---|---|---|---|
| March 27, 2025 | House | Action | Introduction and first reading, referred to | Health Finance and Policy | |
| April 01, 2025 | House | Action | Author added | ||
| February 25, 2026 | House | Action | Author added | ||
| March 12, 2026 | House | Action | Authors added | ||
| March 16, 2026 | House | Action | Committee report, to adopt as amended and re-refer to | Commerce Finance and Policy | |
| Showing the 5 most recent stages. This bill has 7 stages in total. Log in to view all stages | |||||
Meeting documents
You must be logged in to view legislative committee meeting documents.
Citations
You must be logged in to view citations.
Progress through the legislative process
Sponsors
You must be logged in to view sponsors.